Sinocare Displays Chronic Disease Management Solutions at EASD 2026
Sinocare is showcasing its integrated chronic disease management portfolio at the EASD 2026 annual meeting in Milan. The solutions address key stages from risk screening to daily monitoring.
Sinocare presented its integrated chronic disease management portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026), held in Milan from September 28 to October 2, 2026. The company's offerings are designed for home, community pharmacy, and hospital settings, covering various aspects of chronic disease management, including risk screening, daily monitoring, clinical testing, and patient management.
For home care, Sinocare is featuring the Safe AQ max II Blood Glucose Monitoring System, which provides results in five seconds and supports Bluetooth data synchronization. The KUG-11 Glucose, Uric Acid & Ketone Meter offers three-in-one metabolic testing, while the GV-100 Veterinary Blood Glucose Monitoring System is intended for at-home diabetes care for pets.
At community pharmacies, the iCARE-1300 Portable Automatic Multifunction Analyzer enables automated testing of nearly 100 parameters, such as blood glucose, lipid profiles, HbA1c, and renal function, with results available within 3 to 15 minutes. Through its Health Station model, Sinocare is also assisting pharmacies in expanding their chronic disease screening and risk assessment capabilities.
For hospitals, the AGEscan Advanced Glycation End Products Fluorescence Detector allows for non-invasive detection of AGEs without blood sampling, supporting early risk screening. The Safe AQ 8000 Hospital Blood Glucose Smart Management System connects with hospital information systems and integrates data from blood glucose meters and continuous glucose monitoring (CGM) through a Doctor Web Portal, facilitating bedside testing and patient monitoring.
These solutions highlight Sinocare's approach to connecting screening, monitoring, and long-term management across different care settings. The company plans to continue advancing biosensing technologies and integrated healthcare solutions to support more accessible and connected chronic disease management globally.